Arcalyst (Rilonacept) Patent Expiration, LOE Window & CMS Spending

Arcalyst (Rilonacept) by Kiniksa (Uk): Biologic BLA (Purple Book Regime), 0 AB generics, $98.4M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorKiniksa (Uk)
FDA Application & PathwayB125249 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$98.4M
2024 Medicare Part D Spend$53.2M
2024 Medicaid Spend$45.2M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 17.4% 2-yr change)